MYO7A_HUMAN,I1633V,0.243,-,-,-
MYO7A_HUMAN,N1650G,0.441,-,-,-
MYO7A_HUMAN,K1657R,0.619,Altered Transmembrane protein (Pr = 0.26 | P = 7.7e-04); Altered DNA binding (Pr = 0.19 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q1658 (Pr = 0.08 | P = 0.02), None,-
MYO7A_HUMAN,S1666C,0.062,-,-,-
MYO7A_HUMAN,T1674A,0.388,-,-,-
MYO7A_HUMAN,M1675T,0.258,-,-,-
MYO7A_HUMAN,P1677L,0.190,-,-,-
MYO7A_HUMAN,V1695I,0.034,-,-,-
MYO7A_HUMAN,L1700M,0.088,-,-,-
MYO7A_HUMAN,T1702A,0.109,-,-,-
MYO7A_HUMAN,D1720G,0.789,Loss of Phosphorylation at Y1721 (Pr = 0.29 | P = 0.02); Loss of Sulfation at Y1721 (Pr = 0.05 | P = 8.8e-03), ELME000120,-
MYO7A_HUMAN,P1724S,0.280,-,-,-
MYO7A_HUMAN,P1726A,0.307,-,-,-
MYO7A_HUMAN,H1728A,0.513,Gain of Helix (Pr = 0.27 | P = 0.05); Altered Disordered interface (Pr = 0.21 | P = 0.03), None,-
MYO7A_HUMAN,T1729A,0.271,-,-,-
MYO7A_HUMAN,L1730G,0.694,Gain of Intrinsic disorder (Pr = 0.32 | P = 0.03); Loss of Helix (Pr = 0.28 | P = 0.02); Altered Disordered interface (Pr = 0.25 | P = 0.02); Gain of B-factor (Pr = 0.25 | P = 0.03); Altered Stability (Pr = 0.12 | P = 0.03), None,-
MYO7A_HUMAN,S1731G,0.540,Altered Disordered interface (Pr = 0.25 | P = 0.02), None,-
MYO7A_HUMAN,S1731Q,0.699,Altered Disordered interface (Pr = 0.25 | P = 0.02), None,-
MYO7A_HUMAN,V1735W,0.524,Altered Disordered interface (Pr = 0.41 | P = 3.2e-03), ELME000137,-
MYO7A_HUMAN,S1736H,0.363,-,-,-
MYO7A_HUMAN,A1738T,0.117,-,-,-
MYO7A_HUMAN,G1740S,0.515,Gain of Intrinsic disorder (Pr = 0.39 | P = 1.0e-02); Altered Disordered interface (Pr = 0.25 | P = 0.02); Gain of Proteolytic cleavage at W1745 (Pr = 0.12 | P = 0.03), ELME000053|ELME000173,-
MYO7A_HUMAN,S1746G,0.389,-,-,-
MYO7A_HUMAN,L1752M,0.239,-,-,-
MYO7A_HUMAN,L1757V,0.463,-,-,-
MYO7A_HUMAN,K1758L,0.679,, ELME000045|ELME000106|ELME000146,-
MYO7A_HUMAN,K1758R,0.192,-,-,-
MYO7A_HUMAN,L1761V,0.142,-,-,-
MYO7A_HUMAN,E1764Q,0.316,-,-,-
MYO7A_HUMAN,E1765S,0.597,, ELME000053|ELME000202,-
MYO7A_HUMAN,Q1768M,0.552,, ELME000147|ELME000202,-
MYO7A_HUMAN,A1773T,0.552,, None,-
MYO7A_HUMAN,F1774S,0.925,Gain of Acetylation at K1779 (Pr = 0.22 | P = 0.03); Altered Stability (Pr = 0.10 | P = 0.04), ELME000041|ELME000335,-
MYO7A_HUMAN,I1775P,0.579,Gain of Allosteric site at Y1780 (Pr = 0.26 | P = 9.2e-03); Gain of Acetylation at K1779 (Pr = 0.23 | P = 0.02), ELME000041,-
MYO7A_HUMAN,I1775V,0.102,-,-,-
MYO7A_HUMAN,A1776P,0.877,Gain of Allosteric site at Y1780 (Pr = 0.25 | P = 9.6e-03); Gain of Acetylation at K1779 (Pr = 0.22 | P = 0.03), ELME000041,-
MYO7A_HUMAN,V1777A,0.531,Loss of Allosteric site at Y1780 (Pr = 0.25 | P = 0.02); Gain of Acetylation at K1779 (Pr = 0.19 | P = 0.05), ELME000041,-
MYO7A_HUMAN,T1789A,0.205,-,-,-
MYO7A_HUMAN,V1792I,0.168,-,-,-
MYO7A_HUMAN,K1805R,0.513,Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Gain of Allosteric site at F1800 (Pr = 0.22 | P = 0.03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000002|ELME000251,-
MYO7A_HUMAN,S1829R,0.915,Gain of Helix (Pr = 0.29 | P = 0.01); Loss of Loop (Pr = 0.28 | P = 0.02), ELME000062|ELME000233,-
MYO7A_HUMAN,R1832K,0.398,-,-,-
MYO7A_HUMAN,E1835Q,0.690,Altered Ordered interface (Pr = 0.24 | P = 0.05), ELME000149|ELME000335,-
MYO7A_HUMAN,L1843W,0.867,, None,-
MYO7A_HUMAN,L1858H,0.783,, ELME000336,-
MYO7A_HUMAN,H1863P,0.731,, ELME000233,-
MYO7A_HUMAN,P1865V,0.545,Altered Metal binding (Pr = 0.22 | P = 0.05); Altered Coiled coil (Pr = 0.13 | P = 0.03), ELME000233|ELME000313|ELME000333,-
MYO7A_HUMAN,L1871F,0.273,-,-,-
MYO7A_HUMAN,Q1872A,0.555,Gain of Acetylation at K1876 (Pr = 0.20 | P = 0.04); Altered DNA binding (Pr = 0.17 | P = 0.04); Altered Coiled coil (Pr = 0.15 | P = 0.03), ELME000134|ELME000313,-
MYO7A_HUMAN,K1876V,0.664,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Acetylation at K1876 (Pr = 0.25 | P = 0.01); Altered DNA binding (Pr = 0.19 | P = 0.03); Altered Coiled coil (Pr = 0.15 | P = 0.03), ELME000134|ELME000313,-
MYO7A_HUMAN,E1914S,0.706,Altered Metal binding (Pr = 0.44 | P = 5.3e-03); Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Stability (Pr = 0.09 | P = 0.05), ELME000064|ELME000085|ELME000321|PS00006,-
MYO7A_HUMAN,E1919S,0.816,Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Metal binding (Pr = 0.27 | P = 7.8e-03); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered DNA binding (Pr = 0.20 | P = 0.02), ELME000063|ELME000336,-
MYO7A_HUMAN,S1920A,0.665,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Metal binding (Pr = 0.27 | P = 9.1e-03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Loss of Strand (Pr = 0.26 | P = 0.05); Altered DNA binding (Pr = 0.19 | P = 0.03), None,-
MYO7A_HUMAN,S1921T,0.374,-,-,-
MYO7A_HUMAN,K1925P,0.651,Altered Metal binding (Pr = 0.33 | P = 0.01); Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Helix (Pr = 0.27 | P = 0.04); Altered DNA binding (Pr = 0.20 | P = 0.02), ELME000313,-
MYO7A_HUMAN,N1930R,0.438,-,-,-
MYO7A_HUMAN,A1932G,0.447,-,-,-
MYO7A_HUMAN,A1932S,0.243,-,-,-
MYO7A_HUMAN,T1933V,0.272,-,-,-
MYO7A_HUMAN,S1939D,0.596,, ELME000053|ELME000197|ELME000313,-
MYO7A_HUMAN,S1940A,0.300,-,-,-
MYO7A_HUMAN,S1940F,0.676,, ELME000053|ELME000197|ELME000313,-
MYO7A_HUMAN,E1941P,0.688,, ELME000053|ELME000136|ELME000159|ELME000197|ELME000336|ELME000337,-
MYO7A_HUMAN,F1943A,0.938,, ELME000053|ELME000197,-
MYO7A_HUMAN,K1948R,0.628,, None,-
MYO7A_HUMAN,K1952P,0.851,Loss of Strand (Pr = 0.26 | P = 0.04); Altered Transmembrane protein (Pr = 0.17 | P = 0.01), ELME000064|ELME000065|ELME000106|ELME000173,-
MYO7A_HUMAN,A2089T,0.259,-,-,-
MYO7A_HUMAN,K2102R,0.231,-,-,-
MYO7A_HUMAN,N2124S,0.337,-,-,-
MYO7A_HUMAN,Y2136H,0.228,-,-,-
MYO7A_HUMAN,V2138I,0.206,-,-,-
MYO7A_HUMAN,S2139L,0.509,Loss of Relative solvent accessibility (Pr = 0.35 | P = 2.3e-03); Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered Transmembrane protein (Pr = 0.25 | P = 1.3e-03); Altered Metal binding (Pr = 0.24 | P = 0.02), ELME000120|ELME000333|PS00006,-
MYO7A_HUMAN,L2140R,0.928,Altered Ordered interface (Pr = 0.32 | P = 8.8e-03); Altered Transmembrane protein (Pr = 0.24 | P = 1.6e-03); Loss of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered Metal binding (Pr = 0.23 | P = 0.02); Altered Stability (Pr = 0.11 | P = 0.03), ELME000333|PS00006,-
MYO7A_HUMAN,P2143E,0.526,Altered Metal binding (Pr = 0.53 | P = 4.1e-03); Gain of Relative solvent accessibility (Pr = 0.30 | P = 8.4e-03); Gain of Strand (Pr = 0.28 | P = 8.3e-03); Altered Ordered interface (Pr = 0.27 | P = 0.05); Altered Transmembrane protein (Pr = 0.25 | P = 1.5e-03), ELME000052|ELME000333,-
MYO7A_HUMAN,K2144E,0.377,-,-,-
MYO7A_HUMAN,K2144R,0.037,-,-,-
MYO7A_HUMAN,K2144T,0.347,-,-,-
MYO7A_HUMAN,T2145G,0.571,Altered Ordered interface (Pr = 0.28 | P = 0.05); Altered Transmembrane protein (Pr = 0.27 | P = 8.4e-04); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.04); Altered Metal binding (Pr = 0.24 | P = 0.02), ELME000052,-
MYO7A_HUMAN,K2146N,0.436,-,-,-
MYO7A_HUMAN,I2148A,0.569,Altered Stability (Pr = 0.83 | P = 2.8e-04); Altered Transmembrane protein (Pr = 0.28 | P = 4.9e-04); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02), ELME000052|ELME000053|ELME000146,-
MYO7A_HUMAN,T2151K,0.805,Altered Transmembrane protein (Pr = 0.29 | P = 2.0e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Loss of Strand (Pr = 0.26 | P = 0.03); Altered Stability (Pr = 0.10 | P = 0.04), ELME000053,-
MYO7A_HUMAN,S2161P,0.916,Gain of Loop (Pr = 0.27 | P = 0.03); Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Transmembrane protein (Pr = 0.19 | P = 5.9e-03); Loss of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053|ELME000063|ELME000070|ELME000085|PS00001,-
MYO7A_HUMAN,S2162R,0.842,Loss of Loop (Pr = 0.32 | P = 4.1e-03); Altered Ordered interface (Pr = 0.31 | P = 0.01); Gain of ADP-ribosylation at S2162 (Pr = 0.22 | P = 0.02); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Gain of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053|ELME000063|ELME000070|ELME000085|PS00001,-
MYO7A_HUMAN,N2164H,0.653,Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Loop (Pr = 0.29 | P = 7.9e-03); Altered Metal binding (Pr = 0.26 | P = 0.01); Gain of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053|ELME000063|ELME000085,-
MYO7A_HUMAN,F2167L,0.759,Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Loop (Pr = 0.28 | P = 0.01); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000081|ELME000120|ELME000182|ELME000336,-
MYO7A_HUMAN,V2175R,0.919,Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000008|ELME000012|ELME000062|ELME000102|ELME000108|PS00004,-
MYO7A_HUMAN,G2177A,0.784,Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000062|ELME000149,-
MYO7A_HUMAN,G2177P,0.853,Altered Transmembrane protein (Pr = 0.15 | P = 0.01), ELME000062|ELME000149,-
MYO7A_HUMAN,C2182A,0.894,Altered Stability (Pr = 0.16 | P = 0.02); Altered Transmembrane protein (Pr = 0.15 | P = 0.01), ELME000147|ELME000239|ELME000336,-
MYO7A_HUMAN,I2198S,0.926,Gain of Intrinsic disorder (Pr = 0.61 | P = 2.7e-04); Altered Disordered interface (Pr = 0.33 | P = 0.01); Altered Transmembrane protein (Pr = 0.15 | P = 0.02); Gain of O-linked glycosylation at S2196 (Pr = 0.10 | P = 0.05); Altered Stability (Pr = 0.10 | P = 0.04), ELME000052|ELME000053|ELME000063|ELME000163|ELME000182|ELME000202|ELME000336,-
MYO7A_HUMAN,S2199G,0.684,Altered Disordered interface (Pr = 0.30 | P = 0.02), ELME000052|ELME000053|ELME000063|ELME000163|ELME000182|ELME000202|PS00008,-
MYO7A_HUMAN,T2203S,0.402,-,-,-
MYO7A_HUMAN,M2205F,0.550,Loss of Intrinsic disorder (Pr = 0.47 | P = 0.01); Altered Disordered interface (Pr = 0.30 | P = 0.01); Altered DNA binding (Pr = 0.19 | P = 0.02); Loss of Methylation at K2207 (Pr = 0.09 | P = 0.05), None,-
MYO7A_HUMAN,K2207R,0.323,-,-,-
MYO7A_HUMAN,G2210A,0.228,-,-,-
MYO7A_HUMAN,S2211A,0.082,-,-,-
MYO7A_HUMAN,R2212A,0.273,-,-,-
MYO7A_HUMAN,S2213T,0.098,-,-,-
MYO7A_HUMAN,G2214A,0.151,-,-,-
MYO7A_HUMAN,P1726L,0.413,-,-,-
